Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway

Y Xu, Z Lei, J Zhu, L Wan - Biochemical and Biophysical Research …, 2022 - Elsevier
Bladder cancer is a common urinary cancer that still lacks effective treatments. In the present
study, we evaluated the effect of BET inhibitor, mivebresib, in combination with PZ703b, a …
被引用次数：2 相关文章

Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway

Y Xu, Z Lei, J Zhu, L Wan - Biochemical and biophysical …, 2022 - pubmed.ncbi.nlm.nih.gov
Bladder cancer is a common urinary cancer that still lacks effective treatments. In the present
study, we evaluated the effect of BET inhibitor, mivebresib, in combination with PZ703b, a …

Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway.

Y Xu, Z Lei, J Zhu, L Wan - Biochemical and Biophysical Research …, 2022 - europepmc.org
Bladder cancer is a common urinary cancer that still lacks effective treatments. In the present
study, we evaluated the effect of BET inhibitor, mivebresib, in combination with PZ703b, a …

[引用][C] Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway

Y Xu, Z Lei, J Zhu, L Wan - 2022